Laura E. Wallace, MPH

Boehringer Ingelheim Pharma, Germany

Boehringer Ingelheim (Employment)

Poster(s):

• (P-392) Characteristics of Patients with Idiopathic Pulmonary Fibrosis (IPF) Initiating Nintedanib or Pirfenidone Treatment Compared with Untreated Patients in the US